Aktienanalyse zu Protalix Biotherapeutics Inc (PLX)PLXProtalix Biotherapeutics Inc

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Protalix Biotherapeutics Inc is a good buy right now due to its strong recent earnings report showing a net income of $18.3 million for Q1 2026, translating to an EPS of $0.22, which is a significant improvement from the previous year's loss. Additionally, the company has reaffirmed its revenue guidance for 2026, projecting total revenues between $78 million and $83 million, which further supports investor confidence. However, the current RSI of 43.51 indicates that the stock is approaching oversold territory, which could present a buying opportunity. The main risk is the forward P/E ratio of 51.81, suggesting that the stock may be overvalued if growth does not materialize as expected.

2 analysts cover PLX: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.